Clinical characteristics and survival analysis of pediatric Hodgkin lymphoma: a multicenter study.
10.7499/j.issn.1008-8830.2412144
- Author:
Ying LIN
1
;
Li-Li PAN
1
;
Shao-Hua LE
1
;
Jian LI
1
;
Bi-Yun GUO
;
Yu ZHU
;
Kai-Zhi WENG
;
Jin-Hong LUO
;
Gao-Yuan SUN
;
Yong-Zhi ZHENG
1
Author Information
1. Union Clinical Medicine College of Fujian Medical University, Fuzhou 350001, China.
- Publication Type:English Abstract
- Keywords:
Chemotherapy;
Child;
Hodgkin lymphoma;
Prognostic analysis
- MeSH:
Humans;
Hodgkin Disease/pathology*;
Male;
Child;
Female;
Adolescent;
Retrospective Studies;
Child, Preschool;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Prognosis;
Proportional Hazards Models;
Survival Analysis;
Infant
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(6):668-674
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the clinicopathological characteristics and prognostic factors of pediatric Hodgkin lymphoma (HL).
METHODS:A retrospective analysis was conducted on the clinical data of children with newly diagnosed HL from January 2011 to December 2023 at four hospitals: Fujian Medical University Union Hospital, Fujian Medical University Zhangzhou Hospital, First Affiliated Hospital of Xiamen University, and Fujian Children's Hospital. Patients were categorized into low-risk (R1), intermediate-risk (R2), and high-risk (R3) groups based on HL staging and pre-treatment risk factors. The patients received ABVD regimen or Chinese Pediatric HL-2013 regimen chemotherapy. Early treatment response and long-term efficacy were assessed, and prognostic factors were analyzed using the Cox proportional hazards regression model.
RESULTS:The overall complete response (CR) rates after 2 and 4 cycles of chemotherapy were 42% and 68%, respectively. Compared with the ABVD regimen group, patients treated with the HL-2013 regimen in the R1 group showed significantly higher CR rates after both 2 and 4 cycles (P<0.05). However, no statistically significant differences in CR rates were observed between the two regimens in the R2 and R3 groups (P>0.05). The 5-year event-free survival (EFS) rate, overall survival rate, and freedom from treatment failure rate were 83%±4%, 97%±2%, and 88%±4%, respectively. Cox analysis indicated that the presence of a large tumor mass at diagnosis and failure to achieve CR after 4 cycles of chemotherapy were independent risk factors for lower EFS rates (P<0.05).
CONCLUSIONS:Pediatric HL generally has a favorable prognosis. The presence of a large tumor mass at diagnosis and failure to achieve CR after 4 cycles of chemotherapy indicate poor prognosis.
